Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ACQ007
MIFTS: 63

Acquired Immunodeficiency Syndrome

Categories: Infectious diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Acquired Immunodeficiency Syndrome

About this section

MalaCards integrated aliases for Acquired Immunodeficiency Syndrome:

Name: Acquired Immunodeficiency Syndrome 12 3 44 15 73
Acquired Immune Deficiency Syndrome 12 76 3
Acquired Immune Deficiency 12
Aids 12

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:635
ICD10 33 B20
MeSH 44 D000163
NCIt 50 C2851
UMLS 73 C0001175
Sources

Summaries for Acquired Immunodeficiency Syndrome

About this section
Disease Ontology : 12 A Human immunodeficiency virus infectious disease that results in reduction in the numbers of CD4-bearing helper T cells below 200 per µL of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. Opportunistic infections are common in people with AIDS.

MalaCards based summary : Acquired Immunodeficiency Syndrome, also known as acquired immune deficiency syndrome, is related to kaposi sarcoma and cytomegalovirus retinitis. An important gene associated with Acquired Immunodeficiency Syndrome is HCP5 (HLA Complex P5
A total of 245 HIV patients were included in the study. A good correlation between HLA-B*5701 and HCP5 was observed (negative and positive predictive values of 100% and 93%,respectively).
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Zinc and Maraviroc have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are cellular and homeostasis/metabolism

CDC : 3 Help

Wikipedia : 76 Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum... more...

Sources

Related Diseases for Acquired Immunodeficiency Syndrome

About this section

Diseases related to Acquired Immunodeficiency Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 588)
# Related Disease Score Top Affiliating Genes
1 kaposi sarcoma 31.3 CCR5 CSF2 IL6 TNF
2 cytomegalovirus retinitis 31.3 CCR2 CCR5 CSF2 IFNG TNF
3 candidiasis 31.2 CD79A IFNG IL10
4 human immunodeficiency virus type 1 31.1 B2M CCR2 CCR5 CD38 CD4 IFNG
5 syphilis 31.1 B2M CD40LG CD79A
6 pneumonia 31.0 CD40LG IL10 IL6 TNF
7 cytomegalovirus infection 31.0 IFNG IL10 IL6 TNF
8 progressive multifocal leukoencephalopathy 31.0 CD40LG IL2 TNF
9 aids dementia complex 30.9 B2M ITIH4 TNF
10 aspergillosis 30.9 CD79A IFNG IL10
11 intussusception 30.9 CD40LG CD79A IL6
12 uveitis 30.8 IFNG IL10 TNF
13 lymphadenitis 30.8 IFNG IL10 TNF
14 trichosporonosis 30.8 CSF2 IFNG TNF
15 cutaneous leishmaniasis 30.8 IFNG IL10 TNF
16 gingivitis 30.8 CD79A IL6 TNF
17 mucocutaneous leishmaniasis 30.8 CCR5 IL10 TNF
18 sporotrichosis 30.7 CD40LG CD79A IFNG IL10
19 pneumocystosis 30.7 ALB CD4 CD40LG CD79A TNF
20 panuveitis 30.7 CD40LG IL10 TNF
21 meningoencephalitis 30.7 ALB B2M CD40LG CD79A IL6
22 tuberculous peritonitis 30.7 ALB IFNG TNF
23 hemophagocytic lymphohistiocytosis 30.6 B2M IFNG IL10 TNF
24 arthritis 30.6 CSF2 IFNG IL10 IL6 TNF
25 posterior uveitis 30.6 IFNG IL2 TNF
26 smallpox 30.6 CSF2 IFNG IL2 TNF
27 appendicitis 30.6 ALB IL10 IL6 TNF
28 sclerosing cholangitis 30.6 ALB CD40LG TNF
29 osteomyelitis 30.5 IFNG IL6 TNF
30 diarrhea 30.5 ALB CD40LG CD79A TNF
31 central nervous system disease 30.4 CD40LG IFNG IL6 TNF
32 colitis 30.4 IFNG IL10 IL2 IL6 TNF
33 meningitis 30.4 ALB CD40LG IFNG IL10 IL6 TNF
34 skin disease 30.4 CD79A IFNG IL10 TNF
35 bronchiolitis obliterans 30.4 IFNG IL10 IL6 TNF
36 cholangitis 30.4 ALB CD40LG IL6 TNF
37 paracoccidioidomycosis 30.4 IFNG IL10 IL2 IL6 TNF
38 endocarditis 30.3 ALB IL10 IL6 TNF
39 peritonitis 30.3 ALB B2M IL10 IL6 TNF
40 visceral leishmaniasis 30.3 ALB IFNG IL10 IL2 TNF
41 kawasaki disease 30.3 ALB IL10 IL6 TNF
42 spondylitis 30.3 CD40LG IL6 TNF
43 prostatitis 30.3 IL10 IL2 IL6 TNF
44 purpura 30.3 CD40LG CD79A TNF
45 toxoplasmosis 30.3 CCR5 CD40LG CD79A IFNG IL10 IL6
46 demyelinating disease 30.2 CD40LG IFNG IL10 TNF
47 myocarditis 30.2 CD40LG IL6 TNF
48 multiple sclerosis 30.1 CCR5 IFNG IL10 IL2 IL6 TNF
49 lymphoma, non-hodgkin, familial 30.0 B2M CD38 CD40LG CD79A CSF2 IL2
50 herpes zoster 30.0 HCP5 IFNG IL10 IL2

Graphical network of the top 20 diseases related to Acquired Immunodeficiency Syndrome:



Diseases related to Acquired Immunodeficiency Syndrome
Sources

Symptoms & Phenotypes for Acquired Immunodeficiency Syndrome

About this section

MGI Mouse Phenotypes related to Acquired Immunodeficiency Syndrome:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 ALB CCR5 B2M CD38 CD4 CCR2
2 homeostasis/metabolism MP:0005376 10.3 ALB CCR5 B2M CD38 CD4 CCR2
3 hematopoietic system MP:0005397 10.29 CCR5 B2M CD38 CD4 CCR2 CD40LG
4 immune system MP:0005387 10.25 CCR5 B2M CD38 CD4 CCR2 CD40LG
5 cardiovascular system MP:0005385 10.24 CCR2 CCR5 B2M CD40LG IFNG IL10
6 endocrine/exocrine gland MP:0005379 10.24 ALB B2M CD38 CD4 CD40LG IFNG
7 digestive/alimentary MP:0005381 10.21 ALB CCR5 B2M CD4 CCR2 IFNG
8 liver/biliary system MP:0005370 10.11 ALB CCR5 B2M CCR2 IFNG CD79A
9 neoplasm MP:0002006 10.1 ALB CCR5 B2M CCR2 IFNG CD79A
10 integument MP:0010771 10.01 B2M CD4 CSF2 CD40LG IFNG IL10
11 nervous system MP:0003631 10 CCR2 CCR5 B2M CD4 CD40LG IFNG
12 no phenotypic analysis MP:0003012 9.76 CCR5 CD4 CCR2 IFNG CD79A IL10
13 renal/urinary system MP:0005367 9.5 CCR2 ALB CD40LG IFNG CD79A CSF2
14 reproductive system MP:0005389 9.28 CCR5 B2M CD40LG IFNG IL10 CSF2
Sources

Drugs & Therapeutics for Acquired Immunodeficiency Syndrome

About this section

Drugs for Acquired Immunodeficiency Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
2
Maraviroc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 376348-65-1 3002977
3
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 63585-09-1, 4428-95-9 3415
4
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
6
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 723-46-6 5329
7
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
8
Etravirine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 269055-15-4 193962
9
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
10
Enfuvirtide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159519-65-0 16130199
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
12
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
13
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-85-3 3767
14
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
15
Praziquantel Approved, Investigational, Vet_approved Phase 4,Not Applicable 55268-74-1 4891
16
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 155213-67-5 392622
17
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-05-7 2719
18
Ezetimibe Approved Phase 4,Phase 1,Not Applicable 163222-33-1 150311
19
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 134678-17-4 60825
20
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 192725-17-0 92727
21
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5458213 5381226
22
Pentamidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100-33-4 4735
23
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
24
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2 69-65-8 453 6251
25
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
26
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82410-32-0 3454
27
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 635728-49-3, 206361-99-1 213039
28
Ethambutol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 74-55-5 3279 14052
29
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-36-2 5760 446220
30
Tipranavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174484-41-4 65027
31
Zoledronic acid Approved Phase 4,Phase 2,Phase 1 118072-93-8 68740
32
Nevirapine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 129618-40-2 4463
33
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1397-89-3 14956 5280965
34
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 10118-90-8 5281021
35
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 738-70-5 5578
36
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136470-78-5 65140 441300
37
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
38
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073
39
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
40
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69655-05-6 50599
41
Saquinavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 127779-20-8 60787
42
Fluconazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 86386-73-4 3365
43
Desogestrel Approved Phase 4,Phase 2,Not Applicable 54024-22-5 40973
44 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
45
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 561-27-3 5462328
46
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
47
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
48
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2 57-83-0 5994
49
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
50
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 30516-87-1 35370

Interventional clinical trials:

(show top 50) (show all 8984)
# Name Status NCT ID Phase Drugs
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults Unknown status NCT01811823 Phase 4
3 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
4 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
5 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
6 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
7 Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
8 Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
9 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
10 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
11 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
12 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
13 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
14 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
15 Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya Unknown status NCT01015989 Phase 4
16 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
17 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
18 Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Unknown status NCT01875952 Phase 4 Isoniazid
19 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
20 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
21 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
22 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
23 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4 Zidovudine (drug)
24 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
25 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
26 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
27 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
28 Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
29 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
30 Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Unknown status NCT01902186 Phase 4 raltegravir and atazanavir and ritonavir;tenofovir/emtricitabine and atazanavir and ritonavir
31 Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
32 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
33 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
34 PrEP Demonstration Project (PRELUDE Study) Unknown status NCT02206555 Phase 4 emtricitabine/tenofovir disoproxil fumarate
35 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV Unknown status NCT01813357 Phase 4 Rosuvastatin
36 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
37 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
38 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
39 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
40 RAltegravir Switch STudy: Effects on Endothelial Recovery Unknown status NCT01453933 Phase 4 raltegravir
41 Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens Unknown status NCT00940771 Phase 4 Boosted Atazanavir
42 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
43 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
44 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
45 Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
46 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
47 Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation Unknown status NCT02383355 Phase 4 Raltegravir;Continuation of own regimen
48 Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand Unknown status NCT01538940 Phase 4
49 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
50 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Unknown status NCT02686853 Phase 4 Liposomal amphotericin B

Search NIH Clinical Center for Acquired Immunodeficiency Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: acquired immunodeficiency syndrome

Sources

Genetic Tests for Acquired Immunodeficiency Syndrome

About this section
Sources

Anatomical Context for Acquired Immunodeficiency Syndrome

About this section

MalaCards organs/tissues related to Acquired Immunodeficiency Syndrome:

41
Testes, T Cells, Liver, Bone, Kidney, Lung, Brain
Sources

Publications for Acquired Immunodeficiency Syndrome

About this section

Articles related to Acquired Immunodeficiency Syndrome:

(show top 50) (show all 1025)
# Title Authors Year
1
Correlation between Lymphocyte CD4 Count, Treatment Duration, Opportunistic Infection and Cognitive Function in Human Immunodeficiency Virus-Acquired Immunodeficiency Syndrome (HIV-AIDS) Patients. ( 29731931 )
2018
2
Disseminated toxoplasmosis in a patient with advanced acquired immunodeficiency syndrome. ( 29588907 )
2018
3
Self-care of elderly people after the diagnosis of acquired immunodeficiency syndrome. ( 29791625 )
2018
4
The Role of Faith-Based Organizations in the Education, Support, and Services for Persons Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. ( 29362058 )
2018
5
Association of Retinal Vascular Caliber and Age-Related Macular Degeneration in Patients With the Acquired Immunodeficiency Syndrome. ( 29435590 )
2018
6
Total dystrophic onychomycosis caused by<i>Talaromyces marneffei</i>in a patient with Acquired immunodeficiency syndrome on combined anti-retroviral therapy. ( 29251280 )
2018
7
Prevalence and variables associated with an abnormal ankle-brachial index among patients with human immunodeficiency virus/acquired immunodeficiency syndrome. ( 29649953 )
2018
8
Positive Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. ( 29362065 )
2018
9
Epidemiological situation of acquired immunodeficiency syndrome (AIDS)-related mortality in a municipality in northeastern Brazil. A retrospective cross-sectional study. ( 29340503 )
2018
10
Intestinal isosporiasis in patients with acquired immunodeficiency syndrome (AIDS). Pathologic diagnosis in small intestinal mucosal biopsies. ( 29566942 )
2018
11
Multiple Extradural Spinal Meningiomas in a Patient with Acquired Immunodeficiency Syndrome: Case Report and Literature Review. ( 29966786 )
2018
12
Fecal microbiota transplantation for severe complicated C. difficile colitis in a patient with acquired immunodeficiency syndrome. ( 29449093 )
2018
13
Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome. ( 29419696 )
2018
14
Inpatient Outcomes After Elective Lumbar Spinal Fusion for Patients with Human Immunodeficiency Virus in the Absence of Acquired Immunodeficiency Syndrome. ( 29852306 )
2018
15
A Case of Jejunal Intussusception caused by Burkitt Lymphoma in an Acquired Immunodeficiency Syndrome Patient. ( 29637755 )
2018
16
Hemophagocytic lymphohistiocytosis (HLH) secondary to disseminated histoplasmosis in the setting of Acquired Immunodeficiency Syndrome (AIDS). ( 29657917 )
2018
17
Promoting Cardiovascular Health in Patients Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. ( 29362060 )
2018
18
A retrospective analysis of seven patients with acquired immunodeficiency syndrome and pharyngeal and/or laryngeal Talaromyces marneffei infection. ( 28130931 )
2017
19
Point process methods in epidemiology: application to the analysis of human immunodeficiency virus/acquired immunodeficiency syndrome mortality in urban areas. ( 28555483 )
2017
20
The Complete Remission of Acquired Immunodeficiency Syndrome-associated Isolated Central Nervous System Lymphomatoid Granulomatosis: A Case Report and Review of the Literature. ( 28824078 )
2017
21
Imaging Findings of Common Opportunistic Infections and Malignant Tumors in Acquired Immunodeficiency Syndrome Patients. ( 29338829 )
2017
22
Double Morphology: Tertiary Syphilis and Acquired Immunodeficiency Syndrome-A Rare Association. ( 29225977 )
2017
23
Factors affecting antiretroviral treatment adherence among people living with human immunodeficiency virus/acquired immunodeficiency syndrome: A prospective study. ( 29416993 )
2017
24
Toxoplasmic Encephalitis in Patient with Acquired Immunodeficiency Syndrome. ( 28516077 )
2017
25
The End of Acquired Immunodeficiency Syndrome (AIDS) in Singapore - Are We There Yet? ( 29355281 )
2017
26
Advantages of Chinese medicine for patients with acquired immunodeficiency syndrome in rural central China. ( 28887810 )
2017
27
Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome After Initiating Antiretroviral Therapy. ( 27984023 )
2017
28
Case Report: Disseminated Talaromyces (Penicillium) marneffei and Mycobacterium tuberculosis Coinfection in a Japanese Patient with Acquired Immunodeficiency Syndrome. ( 28719322 )
2017
29
Reproductive aspects and knowledge of family planning among women with Acquired Immunodeficiency Syndrome. ( 28562743 )
2017
30
Extensive brain masses and cavitary lung lesions associated with toxoplasmosis and acquired immunodeficiency syndrome. ( 28632476 )
2017
31
Uveitis as an initial manifestation of acquired immunodeficiency syndrome. ( 28201950 )
2017
32
Comparative analysis of cytomegalovirus retinitis and microvascular retinopathy in patients with acquired immunodeficiency syndrome. ( 28944199 )
2017
33
Incidence of Intermediate-stage Age-related Macular Degeneration in Patients With Acquired Immunodeficiency Syndrome. ( 28499708 )
2017
34
Classification of deaths in women with human immunodeficiency virus/acquired immunodeficiency syndrome in pregnancy and childbirth. ( 29160431 )
2017
35
Sinus bradycardia induced by darunavir-ritonavir in a patient with acquired immunodeficiency syndrome. ( 28865059 )
2017
36
Acquired Immunodeficiency Syndrome A Forensic Perspective. ( 29473812 )
2017
37
Study of infections among human immunodeficiency virus/acquired immunodeficiency syndrome patients in Shadan Hospital, Telangana, India. ( 27890948 )
2016
38
Skin aging in patients with acquired immunodeficiency syndrome. ( 27649952 )
2016
39
Oral manifestations of human immunodeficiency virus/acquired immunodeficiency syndrome and their correlation to cluster of differentiation lymphocyte count in population of North-East India in highly active antiretroviral therapy era. ( 27994425 )
2016
40
Analysis and Outcomes of Cataract Surgery in Patients with Acquired Immunodeficiency Syndrome. ( 27082491 )
2016
41
Miliary tuberculosis and acquired immunodeficiency syndrome - 'a cursed duet'. ( 27802849 )
2016
42
Toxoplasmic encephalitis: role of Human Leucocyte Antigens/alleles associated with rapid progression to Acquired Immunodeficiency Syndrome. ( 26786385 )
2016
43
De Novo intracerebral aneurysm in a child with acquired immunodeficiency syndrome. ( 26818175 )
2016
44
Central Nervous System Histoplasmosis in Acquired Immunodeficiency Syndrome. ( 26897273 )
2016
45
Computer simulations of the interaction of human immunodeficiency virus (HIV) aspartic protease with spherical gold nanoparticles: implications in acquired immunodeficiency syndrome (AIDS). ( 27483476 )
2016
46
First report of Cystoisospora belli parasitemia in a patient with acquired immunodeficiency syndrome. ( 26751889 )
2016
47
Recursion-based depletion of human immunodeficiency virus-specific naive CD4(+) T cells may facilitate persistent viral replication and chronic viraemia leading to acquired immunodeficiency syndrome. ( 27515208 )
2016
48
Opportunistic Neurologic Infections in Patients with Acquired Immunodeficiency Syndrome (AIDS). ( 26747443 )
2016
49
Prevalence of Malnutrition and Associated Factors among Hospitalized Patients with Acquired Immunodeficiency Syndrome in Jimma University Specialized Hospital, Ethiopia. ( 27358542 )
2016
50
Multiple coronary aneurysms in a young adult with acquired immunodeficiency syndrome. ( 27168940 )
2016
Sources

Variations for Acquired Immunodeficiency Syndrome

About this section
Sources

Expression for Acquired Immunodeficiency Syndrome

About this section
Search GEO for disease gene expression data for Acquired Immunodeficiency Syndrome.
Sources

Pathways for Acquired Immunodeficiency Syndrome

About this section

Pathways related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.07 B2M CCR2 CCR5 CD4 CD40LG CD79A
2
PEDF Induced Signaling 64
Show member pathways
 13.71 CCR2 CCR5 CD4 CD40LG CSF2 IFNG
3
Akt Signaling 64
Show member pathways
 13.45 CCR2 CCR5 CD4 CD40LG CSF2 IL10
4
PAK Pathway 64
Show member pathways
 13.34 CCR2 CCR5 CD4 CD40LG CSF2 IL10
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.31 B2M CCR2 CCR5 CD4 CD40LG CSF2
6
Allograft rejection 1 37
Show member pathways
 12.9 B2M CD4 CD40LG IFNG IL10 IL2
7
4-1BB Pathway 64
Show member pathways
 12.69 CCR5 CD4 CD40LG IFNG TNF
8
Regulation of IFNA signaling 66
Show member pathways
 12.69 CSF2 IFNG IL10 IL2 IL6 TNF
9
Immune response IL-23 signaling pathway 22
Show member pathways
 12.65 CD4 IFNG IL10 IL2 IL6 TNF
10
Th17 cell differentiation 37
Show member pathways
 12.49 CD4 IFNG IL10 IL2 IL6 TNF
11
NF-kappaB Signaling 4
12.49 B2M CCR2 CD38 CD40LG CD79A IFNG
12
HTLV-I infection 37
12.42 CSF2 IL2 IL6 TNF
13
Folate Metabolism 1
Show member pathways
 12.39 ALB IFNG IL2 IL6 TNF
14
IL-17 Family Signaling Pathways 65
Show member pathways
 12.34 CSF2 IFNG IL6 TNF
15
T cell receptor signaling pathway 37
Show member pathways
 12.32 CCR5 CD4 CD40LG CSF2 IFNG IL10
16
Toxoplasmosis 37
Show member pathways
 12.31 CCR5 CD40LG IFNG IL10 TNF
17
Th1 Differentiation Pathway 65
Show member pathways
 12.28 CD4 IFNG IL10 IL2 IL6 TNF
18
Tuberculosis 37
12.26 IFNG IL10 IL6 TNF
19
C-type lectin receptor signaling pathway 37
Show member pathways
 12.24 IL10 IL2 IL6 TNF
20
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.11 CD4 IFNG IL10 IL2 IL6
21
Spinal Cord Injury 1
12.06 CCR2 IFNG IL2 IL6 TNF
22
IL12-mediated signaling events 1
Show member pathways
 12.03 B2M CCR5 CD4 IFNG IL2
23
Hematopoietic cell lineage 37
11.93 CD38 CD4 CSF2 IL6 TNF
24
Amoebiasis 37
11.92 CSF2 IFNG IL10 IL6 TNF
25
Rheumatoid arthritis 37
11.91 CSF2 IFNG IL6 TNF
26
Jak-Stat Signaling Pathway 67
11.9 CCR2 CCR5 IFNG IL10 IL2 IL6
27
Glucocorticoid receptor regulatory network 1
11.87 CSF2 IFNG IL2 IL6
28
Salmonella infection (KEGG) 37
11.82 CSF2 IFNG IL6
29
Innate Lymphoid Cell Differentiation Pathways 65
11.81 CD4 IFNG IL10 IL2 TNF
30
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.77 CD40LG CSF2 IFNG IL2 TNF
31
Pertussis 37
11.76 IL10 IL6 TNF
32
Lung fibrosis 1
11.73 CCR2 CSF2 IL6 TNF
33
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.71 B2M IFNG IL2 TNF
34
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.68 CD40LG CSF2 IFNG IL2 IL6 TNF
35
B Cell Development Pathways 65
11.64 CD38 CD4 CD40LG IL10
36
Dendritic Cells Developmental Lineage Pathway 65
11.63 CD38 CD4 CSF2 IFNG IL10 IL2
37
Photodynamic therapy-induced AP-1 survival signaling. 1
11.61 IFNG IL2 IL6 TNF
38
Th2 Differentiation Pathway 65
11.56 CD4 IFNG IL10 IL2
39
Aryl Hydrocarbon Receptor Pathway 1
11.55 IFNG IL2 TNF
40
MSP-RON Signaling 64
11.54 CCR2 IFNG TNF
41
Interleukin-10 signaling 66
11.54 CCR2 CCR5 CSF2 IL10 IL6 TNF
42
Malaria 37
11.52 CD40LG IFNG IL10 IL6 TNF
43
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.51 IFNG IL6 TNF
44
Primary immunodeficiency 37
11.43 CD4 CD40LG CD79A
45
African trypanosomiasis 37
11.41 IFNG IL10 IL6 TNF
46
IL-10 Pathway 64
11.4 IL10 IL6 TNF
47
Inflammatory Response Pathway 1
11.37 CD40LG IFNG IL2
48
Development and heterogeneity of the ILC family 1
11.35 IFNG IL6 TNF
49
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.34 CD38 CD4 CD79A CSF2 IFNG IL10
50
IL12 signaling mediated by STAT4 1
11.29 CD4 IFNG IL2
Sources

GO Terms for Acquired Immunodeficiency Syndrome

About this section

Cellular components related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 ALB B2M CD40LG CSF2 IFNG IL10
2 cell surface GO:0009986 9.73 B2M CCR5 CD38 CD4 CD40LG TNF
3 extracellular space GO:0005615 9.61 ALB B2M CD40LG CSF2 IFNG IL10
4 external side of plasma membrane GO:0009897 9.17 B2M CCR2 CCR5 CD4 CD40LG CD79A

Biological processes related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.91 CCR2 CCR5 CD40LG IL10 IL6 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.89 CD4 IFNG IL2 TNF
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.86 CCR2 CCR5 CD38 IL2
4 B cell differentiation GO:0030183 9.81 CD40LG CD79A IL10
5 response to glucocorticoid GO:0051384 9.79 IL10 IL6 TNF
6 positive regulation of interferon-gamma production GO:0032729 9.74 CCR2 IL2 TNF
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CSF2 IFNG IL2 IL6
8 regulation of signaling receptor activity GO:0010469 9.7 CD40LG CSF2 IFNG IL10 IL2 IL6
9 positive regulation of T cell proliferation GO:0042102 9.67 CD4 CD40LG IL2 IL6
10 negative regulation of bone resorption GO:0045779 9.65 CD38 IL6
11 response to molecule of bacterial origin GO:0002237 9.65 B2M IL10
12 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL10 TNF
13 B cell proliferation GO:0042100 9.65 CD40LG CD79A IL10
14 cellular response to lipopolysaccharide GO:0071222 9.65 CCR5 CSF2 IL10 IL6 TNF
15 positive regulation of immunoglobulin secretion GO:0051024 9.64 IL2 IL6
16 positive regulation of podosome assembly GO:0071803 9.64 CSF2 TNF
17 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.63 CD4 CSF2
18 negative regulation of lipid storage GO:0010888 9.62 IL6 TNF
19 humoral immune response GO:0006959 9.62 CCR2 IFNG IL6 TNF
20 endothelial cell apoptotic process GO:0072577 9.61 IL10 TNF
21 fusion of virus membrane with host plasma membrane GO:0019064 9.61 CCR5 CD4
22 negative regulation of cytokine secretion involved in immune response GO:0002740 9.6 IL10 TNF
23 positive regulation of interleukin-23 production GO:0032747 9.58 CSF2 IFNG
24 regulation of immunoglobulin secretion GO:0051023 9.58 CD40LG TNF
25 cytokine-mediated signaling pathway GO:0019221 9.56 CCR2 CCR5 CD4 CSF2 IL10